Strategies targeting stromal cells include using TGF-β signaling inhibitors to reduce CAF activity and disrupting tumor iron homeostasis by targeting iron metabolism-related molecules such as TfR1 and hepcidin. The gene discussed is TFRC; the disease is neoplasm.